Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: soulie p. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu PH, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin AL, Jacquet A, Vaz-Luis I, Herold C, Pistilli B. Balazard F, et al. Among authors: soulie p. J Natl Cancer Inst. 2023 Sep 7;115(9):1099-1108. doi: 10.1093/jnci/djad109. J Natl Cancer Inst. 2023. PMID: 37434306
Circulation chez des patients drépanocytaires : en finir avec les bouchons.
Almeida Rodrigues R, Ardizzone E, Bindschedler L, Caron S, Cuendet S, Chandon P, Didierlaurent A, Soulié P. Almeida Rodrigues R, et al. Among authors: soulie p. Rev Med Suisse. 2024 Mar 27;20(867):672-673. doi: 10.53738/REVMED.2024.20.867.672. Rev Med Suisse. 2024. PMID: 38563543 French. No abstract available.
A fatty acid anabolic pathway in specialized-cells sustains a remote signal that controls egg activation in Drosophila.
Poidevin M, Mazuras N, Bontonou G, Delamotte P, Denis B, Devilliers M, Akiki P, Petit D, de Luca L, Soulie P, Gillet C, Wicker-Thomas C, Montagne J. Poidevin M, et al. Among authors: soulie p. PLoS Genet. 2024 Mar 14;20(3):e1011186. doi: 10.1371/journal.pgen.1011186. eCollection 2024 Mar. PLoS Genet. 2024. PMID: 38483976 Free PMC article.
IPCI et radiothérapie : main dans la main contre le cancer.
Leyss S, Liborova K, Maître M, Manghetti L, Mencier L, Soulié P, Guilhen C. Leyss S, et al. Among authors: soulie p. Rev Med Suisse. 2022 Nov 30;18(806):2303-2305. doi: 10.53738/REVMED.2022.18.806.2303. Rev Med Suisse. 2022. PMID: 36448954 French. No abstract available.
Testostérone: une générosité sous contrôle.
Moudarres L, Najand G, Roch L, Schwitzguebel VM, Seddiki W, Soulié P, Vacher G, Carnesecchi S. Moudarres L, et al. Among authors: soulie p. Rev Med Suisse. 2022 Oct 5;18(798):1880-1881. doi: 10.53738/REVMED.2022.18.798.1880. Rev Med Suisse. 2022. PMID: 36200968 French. No abstract available.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Contraceptive Use in Premenopausal Women With Early Breast Cancer.
Lambertini M, Massarotti C, Havas J, Pistilli B, Martin AL, Jacquet A, Coutant C, Coussy F, Mérimèche AD, Lerebours F, Rousset-Jablonski C, Jouannaud C, Rigal O, Fournier M, Soulie P, Franzoi MA, Del Mastro L, Partridge AH, André F, Vaz-Luis I, Di Meglio A. Lambertini M, et al. Among authors: soulie p. JAMA Netw Open. 2022 Sep 1;5(9):e2233137. doi: 10.1001/jamanetworkopen.2022.33137. JAMA Netw Open. 2022. PMID: 36149651 Free PMC article.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.
376 results